The methods, compositions and systems provided herein use functionalized beads to detect a target microparticle in a test sample, the method comprising (a) contacting the test sample containing the target microparticle with a plurality of functionalized beads. The size of the target microparticle is less than 1 μm. The functionalized beads comprise beads coated with molecules of a capture agent, and at least some molecules of the capture agent bind to the target microparticle, thereby forming target microparticle-loaded beads comprising the functionalized beads and the target microparticle. The method further comprises (b) detecting the target microparticle-loaded beads using a flow cytometer, thereby detecting the presence of the target microparticle in the test sample, and the target microparticle-loaded the beads are detected with the detection limit that ranges from 10 microparticles per ml to 10e4 microparticles per ml.

Immunogenic potential of a virus-like particle (VLP) for use in developing a vaccine is predicted by comparing order parameters of the VLP and a target virus. The method may include determining a numerical value of an order parameter and relative composition of viral coat proteins of a target virion (virus). A numerical value of an order parameter and relative composition of the surface proteins of a VLP is also determined. The numerical value of the order parameter and relative composition of the viral coat proteins of the target virion (virus) are compared to the numerical value of the order parameter and relative composition of the VLP to determine if the VLP satisfies pre-defined matching criteria indicative of high immunogenic potential and corresponding vaccine efficacy.

The present description relates to a Corona antigen having a Corona nucleocapsid specific amino acid sequence, compositions, and reagent kits having the same and methods of producing it. Also encompassed are methods of detecting anti-Corona antibodies in samples using the Corona antigen, and methods of differential diagnosis of an immune response in a patient due to natural Corona infection or due to vaccination against Corona.

Disclosed herein is a system and method for transistor pathogen virus detector in which one embodiment may include a substrate layer, a silicon dioxide layer on the substrate layer, a nanocrystalline diamond layer on the silicon dioxide layer, a graphene oxide layer on the nanocrystalline diamond layer, fluorinated graphene oxide portions; and a linker layer, the linker layer including a plurality of pathogen receptors.

A method of determining the presence or absence of an antibody in a sample, the method comprising the steps of: (a) contacting the sample with a lysis composition comprising: (i) a quaternary ammonium compound; and (ii) a non-ionic surfactant; and (b) contacting the sample and the lysis composition with an antibody detection device.

The invention relates to methods and kits for detecting a virus, e.g., a respiratory virus such as a coronavirus, in a biological sample. The invention also relates to methods and kits for detecting and/or quantifying biomarkers, e.g., antibody biomarkers against a viral antigen; inflammatory and/or tissue damage response biomarkers; and/or extracellular vesicles in response to a viral infection.

Provided herein, in some aspects, are polypeptide monomers comprising an angiotensin-converting enzyme 2 (ACE2) ectodomain and an oligomerization domain. Also provided herein are oligomeric complexes comprising ACE2 monomers. Methods of using such to monomers and oligomeric complexes for the diagnosis, prevention, and treatment of viral infections such as the coronavirus are also provided.

The present disclosure relates to a method for the simultaneous qualitative and quantitative analysis of a plurality of biomarkers contained in a sample, including: capturing one or more biomarkers on a substrate configured to bind a plurality of biomarkers to a plurality of binding sites, wherein binding sites bind at least two biomarkers, and wherein when one or more biomarkers are present forming one or more bound biomarkers-of-interest; contacting the one or more bound biomarkers-of-interest with one or more fluorescent binding partners to form one or more fluorescent complexes; contacting the substrate with a source of collimated, polarized light, wherein the source of collimated polarized light emits light at a predetermined wavelength for transferring energy to surface plasmons and excite fluorescence of the one or more fluorescent complexes; and detecting emission light of fluorescent complexes; and determining the type and/or quantity of plurality of biomarkers.

According to one embodiment, a detection device includes a sensor element and a probe molecule. The probe molecule is immobilized at the sensor element. The probe molecule associates with a receptor exposed at a surface of a detection target. The sensor element detects cleavage of the receptor having associated with the probe molecule.

This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against targets that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes.